10:15 AM EDT, 05/21/2024 (MT Newswires) -- GSK (GSK) said Tuesday that its depemokimab reduced asthma attacks in two phase 3 clinical trials that evaluated the efficacy and safety of the potential treatment compared with placebo in patients with severe asthma.

The trials met their primary endpoints of a lower annualized rate of clinically significant asthma attacks over 52 weeks, the company said.

Further analysis of the results is pending, the company said.

Currently, depemokimab is not approved in any country, GSK said.

Price: 44.65, Change: +0.06, Percent Change: +0.13